Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462865 · ClinicalTrials.gov registry record · Phase 2
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
A Phase 2 study, sponsored by Brown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00462865 is a Phase 2 study that was terminated before completion, run by Brown University. The registered enrollment target is 18 participants.
The verdict
NCT00462865, a Phase 2 study, was terminated before completion, sponsored by Brown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Women with breast cancer who are not eligible for breast conserving surgery or who have node-involvement are sometimes treated with chemotherapy up front, in hopes of allowing for a woman to keep her breast and decreasing the size of the excision for her breast cancer. While current research has shown that survival is the same whether women are treated with chemotherapy first or surgery first for breast cancer, the investigators do not yet know how to treat women with persistent breast cancer after she has received primary chemotherapy. This study looks at the use of a combination regimen of two agents (gemcitabine and capecitabine), both of which are active in breast cancer, and using Avastin to see if this regimen can be given to women treated with primary chemotherapy and then surgery, considered to be at high risk of relapse.
Interventions
- DRUG Gemcitabine and Capecitabine and Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-11 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00462865
The ClinicalTrials.gov registry entry for NCT00462865 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine and Capecitabine and Avastin is the first listed.
NCT00462865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00462865 about?
NCT00462865 is a clinical study titled "Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse". Women with breast cancer who are not eligible for breast conserving surgery or who have node-involvement are sometimes treated with chemotherapy up front, in hopes of allowing for a woman to keep her breast and decreasing the size of the excision for her breast cancer. While current research has sho...
What is the current status of trial NCT00462865?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2007-11. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00462865?
The interventions under investigation include: Gemcitabine and Capecitabine and Avastin (DRUG).
Who is sponsoring clinical trial NCT00462865?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.